The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
Abstract Background Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion. Methods The subjects were 102 UC patients who...
Main Authors: | Ohtaki Yuichiro, Uchiyama Kan, Kamiya Hirotaka, Moriizumi Eri, Yamada Moe, Aoki Yuma, Watanabe Toshimune, Kiryu Sachie, Suzuki Sizuka, Matsumoto Yoshihiro, Ito Zensho, Ohkusa Toshifumi, Koido Shigeo, Saruta Masayuki |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-08-01
|
Series: | BMC Gastroenterology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12876-022-02474-9 |
Similar Items
-
Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
by: Yuichiro Ohtaki, et al.
Published: (2023-02-01) -
Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis
by: Yu. P. Uspenskiy, et al.
Published: (2022-03-01) -
The Importance of Objective Stool Classification in Fecal 1H-NMR Metabolomics: Exponential Increase in Stool Crosslinking Is Mirrored in Systemic Inflammation and Associated to Fecal Acetate and Methionine
by: Leon Deutsch, et al.
Published: (2021-03-01) -
Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms
by: O. V. Knyazev, et al.
Published: (2022-08-01) -
Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
by: Haruhiko Ogata, et al.
Published: (2017-07-01)